Tibolone
Postmenopausal Bone Loss
Dana-Farber Cancer InstituteSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Postmenopausal Bone Loss cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Arzoxifene Eli Lilly and Company | Phase 3 | BB |
Denosumab Aristotle University Of Thessaloniki | Phase 4 | B |
ALENDRONIC ACID Aristotle University Of Thessaloniki | Phase 4 | B |
Liuwei Dihuang Pills xuhuijuan | Phase 2 | CCC |
Xulin Jiangu Granules Fujian Academy of Traditional Chinese Medicine | Early Phase 1 | C |
Same molecule, other indications
Tibolone is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →